Zurn AD[au] - Search Results

Year	Number of Results
1976	2
1977	1
1978	1
1979	1
1982	1
1986	1
1987	1
1988	2
1990	2
1991	3
1993	1
1994	2
1996	6
1997	3
1998	5
2000	5
2001	2
2002	2
2005	4
2006	2
2007	1
2008	2
2009	2
2022	0

1

Regeneration failure in the CNs: cellular and molecular mechanisms.

Zurn AD, Bandtlow CE. Zurn AD, et al. Adv Exp Med Biol. 2006;557:54-76. doi: 10.1007/0-387-30128-3_4. Adv Exp Med Biol. 2006. PMID: 16955704 Review. No abstract available.

2

Combined effects of GDNF, BDNF, and CNTF on motoneuron differentiation in vitro.

Zurn AD, Winkel L, Menoud A, Djabali K, Aebischer P. Zurn AD, et al. J Neurosci Res. 1996 Apr 15;44(2):133-41. doi: 10.1002/(SICI)1097-4547(19960415)44:2<133::AID-JNR5>3.0.CO;2-E. J Neurosci Res. 1996. PMID: 8723221

3

Acetylcholine receptor and myasthenia gravis.

Fulpius BW, Zurn AD, Granato DA, Leder RM. Fulpius BW, et al. Among authors: zurn ad. Ann N Y Acad Sci. 1976;274:116-29. doi: 10.1111/j.1749-6632.1976.tb47680.x. Ann N Y Acad Sci. 1976. PMID: 786106 Review. No abstract available.

4

Sustained delivery of GDNF: towards a treatment for Parkinson's disease.

Zurn AD, Widmer HR, Aebischer P. Zurn AD, et al. Brain Res Brain Res Rev. 2001 Oct;36(2-3):222-9. doi: 10.1016/s0165-0173(01)00098-4. Brain Res Brain Res Rev. 2001. PMID: 11690619 Review.

5

Neurotransmitter plasticity in the sympathetic nervous system: influence of external factors and possible physiological implications.

Zurn AD. Zurn AD. Life Sci. 1991;48(19):1799-808. doi: 10.1016/0024-3205(91)90234-3. Life Sci. 1991. PMID: 1674975 Review.

6

The role of humoral immunity in myasthenia gravis.

Zurn AD, Fulpius BW. Zurn AD, et al. Prog Brain Res. 1979;49:435-40. doi: 10.1016/S0079-6123(08)64655-5. Prog Brain Res. 1979. PMID: 229518 Review. No abstract available.

7

A new low-molecular-weight component promoting adrenergic development in cultured chick sympathetic neurons.

Zurn AD. Zurn AD. J Neurosci. 1987 Nov;7(11):3566-73. doi: 10.1523/JNEUROSCI.07-11-03566.1987. J Neurosci. 1987. PMID: 2890720 Free PMC article.

8

Treatment of Parkinson's disease. Symptomatic cell therapies: cells as biological minipumps.

Zurn AD, Tseng J, Aebischer P. Zurn AD, et al. Eur Neurol. 1996;36(6):405-8. Eur Neurol. 1996. PMID: 8954314 Review. No abstract available.

9

Lentivirus-mediated expression of glutathione peroxidase: neuroprotection in murine models of Parkinson's disease.

Ridet JL, Bensadoun JC, Déglon N, Aebischer P, Zurn AD. Ridet JL, et al. Among authors: zurn ad. Neurobiol Dis. 2006 Jan;21(1):29-34. doi: 10.1016/j.nbd.2005.06.003. Epub 2005 Jul 14. Neurobiol Dis. 2006. PMID: 16023352

10

Differential proteoglycan expression in two spinal cord regions after dorsal root injury.

Waselle L, Quaglia X, Zurn AD. Waselle L, et al. Among authors: zurn ad. Mol Cell Neurosci. 2009 Dec;42(4):315-27. doi: 10.1016/j.mcn.2009.08.004. Epub 2009 Aug 14. Mol Cell Neurosci. 2009. PMID: 19683574

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results